INTELLISEP
DEAD

Serial Number

90011832

Owner

Cytovale Inc.

Attorney

Holly Pranger

Filing Date

Jun 19, 2020

Add to watchlist:

No watchlists yet
View on USPTO

INTELLISEP Trademark

Serial Number: 90011832

INTELLISEP is a trademark filed by Cytovale Inc. on June 19, 2020. The trademark is classified under Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Cytovale Inc. (4 trademarks)

San Francisco, CA 94134

Entity Type: 03

Trademark Details

Filing Date

June 19, 2020

Registration Date

Not Registered

Published for Opposition

October 26, 2021

Goods & Services

medical diagnostic apparatus for analysis of biomarker levels and/or relative expression of host response genes, medical diagnostic apparatus for analyzing gene expression tests using bioinformatics and machine learning algorithms, medical diagnostic apparatus for analyzing gene expression tests, gene expression profiling assays, genetic information, protein biomarkers, clinical data and/or demographic information to aid treatment decisions; sample preparation devices for medical diagnostic purposes in the nature of lysing apparatus in the nature of bd lyse wash assistant, coulter qprep, and related recorded data management software sold as a unit; diagnostic test apparatus for medical use for analysis of gene expression, protein expression, metabolite expression, inflammation, immune- suppression, immune disorders; medical and medical diagnostic apparatus for use in analysis of gene expression tests, analysis of gene expression profiling assays, analyzing genetic information, analyzing and detecting protein biomarkers, analyzing clinical data, and/or analyzing demographic information; point of care medical devices, namely, polymerase chain reaction (pcr) testing equipment for analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders; medical devices for use in the treatment of sepsis, cancer and other immune-mediated conditions in the fields of oncology, hematology, and for diagnosis and treatment of sepsis; medical testing kits comprising apparatus for taking blood, apparatus for blood analysis, test tubes, and cartridges for cancer and other immune-mediated conditions; apparatus for diagnostic purposes, namely, medical diagnostic apparatus for testing for cancer and other immune-mediated conditions in the fields of oncology and hematology; automated medical instruments, namely, host-response testing equipment, cytometers which use electronics and optical fluorescence flow cytometry to analyze human cells; ultraviolet visible and near infrared fluorescence analyzers for medical use and components therefor; imaging platforms, namely, medical imaging apparatus for imaging and analysis of cells and cell organelles, molecular diagnostics and imaging cytometry for medical use; medical micro imaging apparatuses for imaging and analysis of bacteriums, viruses, cells and cell organelles for medical use and components therefor; medical micro imaging apparatuses for molecular diagnostics and cytometry for medical diagnostic use and components therefor; medical apparatuses for the examination and analysis of proteins, peptides, antibodies and molecules for medical diagnostic use and components therefor; digital imaging platforms, namely, medical micro imaging apparatus for acquiring and processing microscopic images for medical diagnostic use; digital imaging platforms, namely, medical micro imaging apparatus for use in the examination of cells, proteins and peptides for medical diagnostic use; diagnostic apparatus for medical use, namely, computed tomography scanners, fluorescent microscope systems comprised of optical detection modalities, apparatus in the nature of apparatus for performing complete blood count measurements and measurements of monocyte distribution with magnification objective for use in performing fluorescent antibody technique analysis and fluorescent protein technique analysis; diagnostic apparatus for medical use, namely, automatic cell sorting systems comprised of apparatus for performing single-cell analysis, optical detection modalities apparatus in the nature of optical measurement equipment, electrical detection modalities apparatus for medical diagnostic purposes, mechanical detection modalities apparatus for determining lateral displacement for medical diagnostic purposes; flow cytometers for use in flow cytometry analysis and in fluorescence activated cell sorting for medical diagnostic purposes; flow cytometers

medical services; medical treatment of sepsis, cancer and immune-mediated diseases; medical analysis services in the fields of cytometry, oncology, and hematology

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 14, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 14, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 10, 2023 EXRA
SOU EXTENSION 3 GRANTED
Jun 9, 2023 EX3G
SOU EXTENSION 3 FILED
Jun 8, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 8, 2023 EEXT
ASSIGNED TO EXAMINER
Jan 17, 2023 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 15, 2022 EXRA
SOU EXTENSION 2 GRANTED
Dec 14, 2022 EX2G
SOU EXTENSION 2 FILED
Dec 12, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 12, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 20, 2022 EXRA
SOU EXTENSION 1 GRANTED
May 19, 2022 EX1G
DIVISIONAL PROCESSING COMPLETE
May 19, 2022 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 14, 2022 AITU
SOU EXTENSION 1 FILED
May 9, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
May 9, 2022 EEXT
DIVISIONAL REQUEST RECEIVED
May 2, 2022 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
May 2, 2022 ERTD
TEAS STATEMENT OF USE RECEIVED
May 2, 2022 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 21, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 26, 2021 NPUB
PUBLISHED FOR OPPOSITION
Oct 26, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 6, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 21, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 21, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 21, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 21, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 21, 2021 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 29, 2021 GNRN
NON-FINAL ACTION E-MAILED
Mar 29, 2021 GNRT
NON-FINAL ACTION WRITTEN
Mar 29, 2021 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 23, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 23, 2021 CRFA
ASSIGNED TO LIE
Feb 22, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 18, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 15, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 15, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 15, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 17, 2020 NWOS
NEW APPLICATION ENTERED
Jun 23, 2020 NWAP